Osteopontin deficiency aggravates hepatic injury induced by ischemia-reperfusion in mice

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Patouraux, S ^a,b,c   Rousseau, D ^a,b   Rubio, A ^a,b   Bonnafous, S ^a,b,d   Lavallard, V J ^a,b   Lauron, J ^a,b   Saint Paul, M C ^a,b,c   Bailly Maitre, B ^a,b   Tran, A ^a,b,d   Crenesse, D ^a,b,e   Gual, P ^a,b  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c PASTEUR HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Hepatic injury; Hepatocyte; Ischemia reperfusion; Macrophage; Osteopontin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OSTEOPONTIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; LEUKOCYTE ACTIVATION; LIVER CELL; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADENOSINE TRIPHOSPHATE; ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; CELL LINE; DISEASE MODELS, ANIMAL; HEPATOCYTES; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; NITRIC OXIDE SYNTHASE TYPE II; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-BCL-2; REPERFUSION INJURY; RNA INTERFERENCE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; WARM ISCHEMIA;

EID: 84901049580     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.174     Document Type: Article

References (42)

1. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583-G589.
2. de Groot H, Rauen U. Ischemia-reperfusion injury: processes in pathogenetic networks: a review. Transplant Proc 2007; 39: 481-484.
3. Peralta C, Jimenez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. J Hepatol 2013; 59: 1094-1106.
4. Hamada T, Duarte S, Tsuchihashi S, Busuttil RW, Coito AJ. Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am J Pathol 2009; 174: 2265-2277.
5. Taniai H, Hines IN, Bharwani S, Maloney RE, Nimura Y, Gao B et al. Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: role for NO and Kupffer cell-derived oxidants. Hepatology 2004; 39: 1544-1552.
6. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009; 58: 125-133.
7. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004; 287: G264-G273.
8. Kawashima R, Mochida S, Matsui A, YouLuTu ZY, Ishikawa K, Toshima K et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999; 256: 527-531.
9. Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res 2014; 44: 22-30.
10. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012; 7: e35612.
11. Chidlow G, Wood JP, Manavis J, Osborne NN, Casson RJ. Expression of osteopontin in the rat retina: effects of excitotoxic and ischemic injuries. Invest Ophthalmol Vis Sci 2008; 49: 762-771.
12. Kossmehl P, Schonberger J, Shakibaei M, Faramarzi S, Kurth E, Habighorst B et al. Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. J Mol Med (Berl) 2005; 83: 626-637.
13. Baliga SS, Merrill GF, Shinohara ML, Denhardt DT. Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen. PLoS One 2011; 6: e14568.
14. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 2001; 50: 1482-1490.
15. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 1994; 269: 711-715.
16. Truong LD, Sheikh-Hamad D, Chakraborty S, Suki WN. Cell apoptosis and proliferation in obstructive uropathy. Semin Nephrol 1998; 18: 641-651.
17. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-1093.
18. Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int 1999; 56: 74-82.
19. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 2003; 63: 543-553.
20. Vinas JL, Sola A, Jung M, Mastora C, Vinuesa E, Pi F et al. Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance. Am J Physiol Renal Physiol 2010; 299: F234-F242.
21. Zhang ZX, Shek K, Wang S, Huang X, Lau A, Yin Z et al. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J Immunol 2010; 185: 967-973.
22. Bailly-Maitre B, Fondevila C, Kaldas F, Droin N, Luciano F, Ricci JE et al. Cytoprotective gene bi-1 is required for intrinsic protection from endoplasmic reticulum stress and ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 2809-2814.
23. Guo H, Cai CQ, Schroeder RA, Kuo PC. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol 2001; 166: 1079-1086.
24. Gao C, Guo H, Mi Z, Grusby MJ, Kuo PC. Osteopontin induces ubiquitindependent degradation of STAT1 in RAW264.7 murine macrophages. J Immunol 2007; 178: 1870-1881.
25. Sahai A, Pan X, Paul R, Malladi P, Kohli R, Whitington PF. Roles of phosphatidylinositol 3-kinase and osteopontin in steatosis and aminotransferase release by hepatocytes treated with methionine-choline-deficient medium. Am J Physiol Gastrointest Liver Physiol 2006; 291: G55-G62.
26. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53: 106-115.
27. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006; 43(2 Suppl 1): S31-S44.
28. Lorena D, Darby IA, Gadeau AP, Leen LL, Rittling S, Porto LC et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol 2006; 44: 383-390.
29. Koh HS, Matsui A, Mimura S, Inao M, Saitoh E, Ohno A et al. Increased cytoprotective function in the liver of transgenic mice expressing osteopontin in hepatocytes. Hepatol Res 2005; 32: 46-51.
30. Wang Y, Chen B, Shen D, Xue S. Osteopontin protects against cardiac ischemiareperfusion injury through late preconditioning. Heart Vessels 2009; 24: 116-123.
31. Okamoto H, Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther 2012; 30: e198-e209.
32. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/ reperfusion. Kidney Int 1999; 56: 601-611.
33. Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996; 2: 80-86.
34. Yamabe K, Shimizu S, Kamiike W, Waguri S, Eguchi Y, Hasegawa J et al. Prevention of hypoxic liver cell necrosis by in vivo human bcl-2 gene transfection. Biochem Biophys Res Commun 1998; 243: 217-223.
35. Neuman MG. Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci 2001; 38: 109-166.
36. Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008; 135: 956-968.
37. Kim HJ, Lee HJ, Jun JI, Oh Y, Choi SG, Kim H et al. Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53. Proc Natl Acad Sci USA 2009; 106: 15326-15331.
38. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr.. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/ reperfusion injury in the rat. J Clin Invest 1990; 85: 1936-1943.
39. Rudiger HA, Clavien PA. Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology 2002; 122: 202-210.
40. Beraza N, Ludde T, Assmus U, Roskams T, Vander Borght S, Trautwein C. Hepatocytespecific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology 2007; 132: 2504-2517.
41. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol 2006; 101: 1824-1833.
42. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-796.